These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14745340)

  • 1. [Levofloxacine for the treatment of pneumococcal pneumonia: results of a meta-analysis].
    Bru JP; Leophonte P; Veyssier P
    Rev Pneumol Clin; 2003 Dec; 59(6):348-56. PubMed ID: 14745340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Levofloxacin in the treatment of community-acquired pneumococcal pneumonia].
    Léophonte P; Veyssier P
    Presse Med; 1999 Nov; 28(36):1975-9. PubMed ID: 10599260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of ciprofloxacin versus amoxicillin + clavulanic acid or erythromycin for the empiric treatment of community-acquired pneumonia].
    Mouton Y; Beuscart C; Leroy O; Ajana F; Charrel J
    Pathol Biol (Paris); 1991 Jan; 39(1):34-7. PubMed ID: 2011407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S; Erdem H; Pahsa A
    Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
    Echols RM; Tillotson GS; Song JX; Tosiello RL
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral clindamycin 300 mg BID compared with oral amoxicillin/clavulanic acid 1 g BID in the outpatient treatment of acute recurrent pharyngotonsillitis caused by group a beta-hemolytic streptococci: an international, multicenter, randomized, investigator-blinded, prospective trial in patients between the ages of 12 and 60 years.
    Mahakit P; Vicente JG; Butt DI; Angeli G; Bansal S; Zambrano D
    Clin Ther; 2006 Jan; 28(1):99-109. PubMed ID: 16490583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinolones for treatment of nosocomial pneumonia: a meta-analysis.
    Shorr AF; Susla GB; Kollef MH
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S115-22. PubMed ID: 15712099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefuroxime for empiric treatment of community-acquired pneumococcal pneumonia: is there a generation gap?
    Wiener-Well Y; Raveh D; Schlesinger Y; Yinnon AM; Rudensky B
    Chemotherapy; 2009; 55(2):97-104. PubMed ID: 19145079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
    Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?
    Falcó V; Almirante B; Jordano Q; Calonge L; del Valle O; Pigrau C; Planes AM; Gavaldà J; Pahissa A
    J Antimicrob Chemother; 2004 Aug; 54(2):481-8. PubMed ID: 15215226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.
    Li JZ; Winston LG; Moore DH; Bent S
    Am J Med; 2007 Sep; 120(9):783-90. PubMed ID: 17765048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis: ertapenem for complicated intra-abdominal infections.
    Falagas ME; Peppas G; Makris GC; Karageorgopoulos DE; Matthaiou DK
    Aliment Pharmacol Ther; 2008 May; 27(10):919-31. PubMed ID: 18266994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
    Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
    Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.